BE UNIQUE: A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov)

Secukinumab Open Label Roll-over Extension Protocol (clinicaltrials.gov)

A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa (clinicaltrials.gov)

Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)

BE UNIQUE: A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov)

A Multicenter, Prospective, Observational Real-World Study on the Efficacy, Safety, and Influencing Factors of IL-17A Inhibitors in Patients with Moderate-to-Severe Hidradenitis Suppurativa (ChiCTR2600121270)

Clinical Safety and Tolerability of Recombinant Anti-tetanus Toxin Monoclonal Antibody (Siltartoxatug) versus Human Tetanus Immunoglobulin for Post-traumatic Tetanus Passive Immunization: A Multicenter Study (ChiCTR2600120402)

Clinical study of secukinumab in the treatment of chronic sinusitis with nasal polyps (ChiCTR2600119197)

Prospective real-world study: Evaluation of the clinical efficacy and safety of secukinumab or spesolimab in the treatment of hidradenitis suppurativa (ChiCTR2600120670)

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov)

PA0019: A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults (2025-522782-30-00)

ANIMA - Italy: Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population (clinicaltrials.gov)